Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final resu... by Bromberg, Jacoline E C, Issa, Samar, van der Holt, Bronno, van der Meulen, Matthijs, Dirven, Linda, Minnema, Monique C, Seute, Tatjana, Durian, Marc, Cull, Gavin, van der Poel, Marjolein W M, Stevens, Wendy B C, Zijlstra, Josee M, Brandsma, Dieta, Nijland, Marcel, Mason, Kylie D, Beeker, Aart, Abrahamse-Testroote, Martine C J, van den Bent, Martin J, de Jong, Daphne, Doorduijn, Jeanette K

Get full text

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL by Geisler, Christian H., van t' Veer, Mars B., Jurlander, Jesper, Walewski, Jan, Tjønnfjord, Geir, Itälä Remes, Maija, Kimby, Eva, Kozak, Tomas, Polliack, Aaron, Wu, Ka Lung, Wittebol, Shulamiet, Abrahamse-Testroote, Martine C.J., Doorduijn, Jeanette, Ghidey Alemayehu, Wendimagegn, van Oers, Marinus H.J.

Get full text

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia by Vojdeman, Fie Juhl, van't Veer, Mars B., Tjønnfjord, Geir E., Itälä-Remes, Maija, Kimby, Eva, Polliack, Aaron, Wu, Ka L., Doorduijn, Jeanette K., Alemayehu, Wendimagegn G., Wittebol, Shulamiet, Kozak, Tomas, Walewski, Jan, Abrahamse-Testroote, Martine C. J., van Oers, Marinus H. J., Geisler, Christian Hartmann

Get full text

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia by Vojdeman, Fie J., Herman, Sarah E. M., Kirkby, Nikolai, Wiestner, Adrian, van t' Veer, Mars B., Tjønnfjord, Geir E., Itälä-Remes, Maija A., Kimby, Eva, Farooqui, Mohammed Z., Polliack, Aaron, Wu, Ka Lung, Doorduijn, Jeanette K., Alemayehu, Wendimagegn G., Wittebol, Shulamiet, Kozak, Tomas, Walewski, Jan, Abrahamse-Testroote, Martine C. J., van Oers, Marinus H. J., Geisler, Christian H., Niemann, Carsten U.

Get full text